Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial

The Genomic Prostate Score (GPS), performed on biopsy tissue, predicts adverse outcome in prostate cancer (PCa) and has shown promise for improving patient selection for active surveillance (AS). However, its impact on treatment choice in high-risk populations of African Americans is largely unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Adam B., Abern, Michael R., Liu, Li, Wang, Heidy, Hollowell, Courtney M. P., Sharifi, Roohollah, Vidal, Patricia, Kajdacsy-Balla, Andre, Sekosan, Marin, Ferrer, Karen, Wu, Shoujin, Gallegos, Marlene, King-Lee, Patrice, Sharp, Lisa K., Ferrans, Carol E., Gann, Peter H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148420/
https://www.ncbi.nlm.nih.gov/pubmed/33835822
http://dx.doi.org/10.1200/JCO.20.02997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148420/
https://www.ncbi.nlm.nih.gov/pubmed/33835822
http://dx.doi.org/10.1200/JCO.20.02997

Ejemplares similares